AR and prostate carcinoma: We have previously demonstrated that some A‐ring‐substituted and heterocycle‐fused derivatives of DHT acted as potent AR antagonists [37, 46], selectively blocking AR transcription programme in prostate cancer cells, including castration‐resistant models.